Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.33B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 5.96M
Average 4.07M
NUVB Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Nuvation Bio Inc.NYSE: NUVB
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q2 FY2026 selling, general & admin of $42.59M rose 10.7% year over year, behind the +32.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 11.2% from the prior quarter. Over 3 fiscal years it compounded at +68.1% a year.
Context
- Selling, general & admin amounted to 240.9% of revenue in FY2025, down 638.4 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 10 analysts of $577.13M (+280.8%) for the fiscal year ending Dec 2026, a step up from the +118.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $42.59M+11.2% QoQ
- Last fiscal yearDec 2025
- $151.56M+118.9% YoY
- LTMJun 2026
- $158.59M+32.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 151.56M USD
- Year-over-year change
- +118.9%
- 4-year CAGR
- +58.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 151.56M | +118.9% |
| FY2024 | 2024-12-31 | 69.23M | +142.6% |
| FY2023 | 2023-12-31 | 28.53M | -10.6% |
| FY2022 | 2022-12-31 | 31.92M | +31.5% |
| FY2021 | 2021-12-31 | 24.28M | — |
Selling, General & Admin vs competitors
How NUVB compares with its peers on the latest reported figures
- NUVB's LTM Jun 2026 selling, general & admin of $158.59M is the highest of the 11 companies compared; the peer median is $72.73M.
- Its year-over-year change of +32.6% is the 5th highest of 11, against a peer median of +26.7%.
- Selling, general & admin amounts to 93.3% of revenue for NUVB, versus a peer median of 213.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $158.59M | +32.6% | +68.1% | 93.3% | |
| LTM Jun 2026 | $153.89M | +144.6% | +66.0% | — | |
| LTM Jun 2026 | $151.65M | +125.3% | +39.4% | 213.2% | |
| LTM Mar 2026 | $124.38M | +14.7% | +17.9% | 239.0% | |
| LTM Jun 2026 | $100.97M | -24.6% | -19.7% | 32.4% | |
| LTM Jun 2026 | $73.81M | +31.8% | +55.5% | — | |
| LTM Mar 2026 | $71.65M | +50.0% | +6.1% | 396.0% | |
| LTM Sep 2026 | $53.4M | -37.3% | +4.7% | 78.7% | |
| LTM Sep 2026 | $52.81M | +43.5% | +31.4% | — | |
| LTM Sep 2026 | $51.3M | +21.7% | +17.2% | 45802.7% | |
| LTM Mar 2026 | $42.56M | -1.1% | +23.3% | 196.9% | |
| Peer median (excluding NUVB) | $72.73M | +26.7% | +20.6% | 213.2% | |
Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7.87M | 62.9M |
| Cost of Revenue | 0 | 0 | 0 | 7.08M | 8.44M |
| Gross Profit | 0 | 0 | 0 | 795K | 54.46M |
| Gross Margin | — | — | — | 10.1% | 86.6% |
| Research & Development | 69.04M | 87.82M | 71.29M | 524.19M | 115.11M |
| Selling, General & Admin | 24.28M | 31.92M | 28.53M | 69.23M | 151.56M |
| Operating Expenses | 93.32M | 119.73M | 99.82M | 593.42M | 267.52M |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| EBITDA | (86.66M) | (104M) | (75.58M) | (566.92M) | (189.21M) |
| EBITDA Margin | — | — | — | -7200.7% | -300.8% |
| Operating Income | (93.32M) | (119.73M) | (99.82M) | (592.63M) | (213.06M) |
| Operating Margin | — | — | — | -7527.3% | -338.7% |
| Interest Income | 2.96M | 7.45M | 24.61M | 27.06M | 21.43M |
| Interest Expense | 0 | 0 | 0 | 341K | 13.68M |
| Other Income / Expenses | 6.47M | 15.54M | 24.02M | 24.69M | 8.44M |
| Income Before Tax | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Pre-Tax Margin | — | — | — | -7213.8% | -325.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Net Margin | — | — | — | -7213.8% | -325.3% |
| EPS (Basic) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| EPS (Diluted) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| Weighted Avg Shares | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
| Weighted Avg Shares (Diluted) | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.